Intellipharmaceutics International Alpha and Beta Analysis
| IPCIFDelisted Stock | USD 0.04 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Intellipharmaceutics International. It also helps investors analyze the systematic and unsystematic risks associated with investing in Intellipharmaceutics over a specified time horizon. Remember, high Intellipharmaceutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Intellipharmaceutics' market risk premium analysis include:
Beta (7.48) | Alpha 13.83 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Intellipharmaceutics |
Intellipharmaceutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Intellipharmaceutics market risk premium is the additional return an investor will receive from holding Intellipharmaceutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Intellipharmaceutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Intellipharmaceutics' performance over market.| α | 13.83 | β | -7.48 |
Intellipharmaceutics Fundamentals Vs Peers
Comparing Intellipharmaceutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Intellipharmaceutics' direct or indirect competition across all of the common fundamentals between Intellipharmaceutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Intellipharmaceutics or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Intellipharmaceutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Intellipharmaceutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Intellipharmaceutics to competition |
| Fundamentals | Intellipharmaceutics | Peer Average |
| Return On Asset | -0.98 | -0.14 |
| Operating Margin | (106.06) % | (5.51) % |
| Current Valuation | 4.47 M | 16.62 B |
| Shares Outstanding | 33.09 M | 571.82 M |
| Shares Owned By Insiders | 1.70 % | 10.09 % |
| Shares Owned By Institutions | 11.09 % | 39.21 % |
| Number Of Shares Shorted | 714 K | 4.71 M |
Intellipharmaceutics Opportunities
Intellipharmaceutics Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Intellipharmaceutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Intellipharmaceutics or other otcs. Alpha measures the amount that position in Intellipharmaceutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Intellipharmaceutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Intellipharmaceutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intellipharmaceutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Intellipharmaceutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Intellipharmaceutics. Please utilize our Beneish M Score to check the likelihood of Intellipharmaceutics' management manipulating its earnings.
| 4th of June 2024 Upcoming Quarterly Report | View | |
| 30th of November 2023 Next Fiscal Quarter End | View |
Build Portfolio with Intellipharmaceutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Intellipharmaceutics OTC Stock
If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |